Kim Daehyun, Lee Seung Soo, Moon Hyungwon, Park So Yeon, Lee Hak Jong
Department of Nano Science and Technology, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 08826, Korea.
Department of Radiology, Seoul National University Bundang Hospital, 82 Gumi-ro 173, Bundang-gu, Seongnam 13620, Korea.
Pharmaceuticals (Basel). 2020 Dec 23;14(1):6. doi: 10.3390/ph14010006.
Cancer immunotherapy has revolutionized the way different neoplasms are treated. Among the different variations of cancer immunotherapy, the checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis have been validated and are currently used in the clinics. Nevertheless, these therapeutic antibodies are associated with significant side effects and are known to induce immune-related toxicities. To address these issues, we have developed an immune-microbubble complex (IMC) which not only reduces the toxicities associated with the antibodies but also enhances the therapeutic efficacy when combined with focused ultrasound. The concept of IMCs could be applied to any type of antibody-based treatment regimens to maximize their therapeutic potential.
癌症免疫疗法彻底改变了不同肿瘤的治疗方式。在癌症免疫疗法的不同变体中，靶向程序性细胞死亡蛋白1（PD-1）/程序性死亡配体1（PD-L1）轴的检查点抑制剂已得到验证，目前正在临床中使用。然而，这些治疗性抗体与显著的副作用相关，并且已知会诱导免疫相关毒性。为了解决这些问题，我们开发了一种免疫微泡复合物（IMC），它不仅降低了与抗体相关的毒性，而且在与聚焦超声联合使用时还提高了治疗效果。IMC的概念可应用于任何基于抗体的治疗方案，以最大限度地发挥其治疗潜力。
